Quadrivalent split-virion influenza vaccine in 3–8-year-old children

Phase 4, randomised, open-label trial of quadrivalent split-virion inactivated influenza vaccine in influenza (3 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Hemagglutination inhibition (HI) antibody seroconversion rate at 28 days after the final vaccine dose for each influenza strain, Hemagglutination inhibition (HI) antibody protection rate at 28 days after the final vaccine dose for each influenza strain and 2 more. Started Oct 2021; status: completed.